Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704477 | 0.90 | FPR2 (0.35) | LRRK2SLC16A3SLC16A1MCTS1SMN1; SMN2 | |
| SCHEMBL2131687 | 0.90 | FPR2 (0.39) | FPR2 | |
| SCHEMBL1704326 | 0.89 | IKBKB (0.36) | — | |
| SCHEMBL1704456 | 0.89 | IKBKB (0.41) | SLC16A3SLC16A1MCTS1FPR2 | |
| SCHEMBL1704159 | 0.87 | IKBKB (0.44) | FPR2 | |
| SCHEMBL2327570 | 0.87 | LRRK2 (0.36) | LRRK2SLC16A3SLC16A1MCTS1SMN1; SMN2 | |
| SCHEMBL1703791 | 0.84 | FPR2 (0.46) | LRRK2SLC16A3SLC16A1MCTS1FPR2 | |
| SCHEMBL1704368 | 0.84 | LRRK2 (0.34) | LRRK2SLC16A3SLC16A1MCTS1SMN1; SMN2 | |
| SCHEMBL1704482 | 0.84 | MAPK14 (0.34) | FPR2 | |
| SCHEMBL2332003 | 0.82 | FYN (0.39) | LRRK2SLC16A3SLC16A1MCTS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | claimed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | claimed |
| US-8580831-B2 | Fluorinated aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | AFF1, SULT2A1, NAT1 | LRRK2 3073/4885SLC16A3 2799/4885SLC16A1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.